- The disease
- This entry does not describe a drug in clinical development for a specific disease. IDT Australia operates as a contract development and manufacturing organisation (CDMO), providing formulation and manufacturing services for specialty oral dosage forms. Customers include pharmaceutical companies that require these services for their own drug products. The scope of services noted includes dosage forms for cannabis- and psychedelic-derived medicines.
- What the asset is trying to do
- As a CDMO, IDT Australia does not itself hold a novel drug mechanism. The company provides technical services -- including formulation development, analytical testing, and manufacturing -- to third-party sponsors who own the underlying drug assets. The specific oral dosage technologies offered by IDT Australia are based on publicly disclosed technical specifications.
- What the trial is measuring, and why it matters
- This asset is a commercial manufacturing business rather than a clinical-stage programme, so there are no clinical trial endpoints to report. Business performance is measured through financial metrics disclosed in periodic ASX filings, including revenue and guidance figures referenced in IDT Australia's 1HFY26 results (ASX announcement, 17 February 2026) and March Quarter Update (ASX announcement, 28 April 2026). Specific revenue figures and guidance details are pending review of those filings.
- Commercial context
- IDT Australia is an ASX-listed CDMO (ticker: IDT). The company has disclosed positive FY26 guidance in its March Quarter Update (ASX announcement, 28 April 2026) and reported first-half FY26 results (ASX announcement, 17 February 2026). Specific revenue figures, contract values, and client details are pending review of those filings. No pipeline drug asset approval status, deal comparables, or lead-asset designation applies to this manufacturing services entry.